

LA JOLLA PHARMACEUTICAL CO

Form 8-K

April 01, 2003

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): March 31, 2003

La Jolla Pharmaceutical Company

---

(Exact Name of Registrant as Specified in Charter)

Delaware

---

(State or Other Jurisdiction  
of Incorporation)

0-24274

---

(Commission  
File Number)

33-0361285

---

(IRS Employer  
Identification No.)

6455 Nancy Ridge Drive, San Diego, California

---

(Address of Principal Executive Offices)

92121

---

(Zip Code)

Registrant's telephone number, including area code: (858) 452-6600

N/A

---

(Former Name or Former Address, if Changed Since Last Report)

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

**SIGNATURES**

**EXHIBIT INDEX**

**EXHIBIT 99.1**

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On March 31, 2003, the Company issued a press release announcing that Matthew Linnik, Ph.D., the Company's Chief Scientific Officer and Executive Vice President of Research, would present at the Biomarkers for the Assessment of Systemic Lupus Erythematosus Conference on March 31, 2003. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**La Jolla Pharmaceutical Company**

Date: April 1, 2003

By: /s/ David Duncan, Jr.

\_\_\_\_\_  
Chief Financial Officer

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release